Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Gustave Roussy Prize : A New Award for Innovation in Oncology
The Institute is launching the Gustave Roussy Prize to mark the 150th anniversary of the birth of its visionary founder.
Published on
Changed on
The Institute is launching the Gustave Roussy Prize to mark the 150th anniversary of the birth of its visionary founder. With an endowment of €200,000, this scientific award will annually recognize a researcher whose discoveries in the fight against cancer have a major impact on patient care.
Born 150 years ago, Professor Gustave Roussy permanently transformed oncology by establishing the first consultation entirely dedicated to cancer patients in 1921. With the launch of the Gustave Roussy Prize, the Institute pays tribute to his legacy by annually honoring a leading global figure in oncology whose discoveries improve cancer patient care, as well as contribute to a better understanding and prevention of the disease.
Applications must be submitted by December 20, 2024
For this inaugural edition of the Gustave Roussy Prize, applications must be submitted no later than December 20, 2024, via the following link: https://forms.office.com/e/rBSaqphxwG.
The jury, composed of international experts independent of Gustave Roussy, will evaluate submissions based on the impact of the discoveries and their direct benefits for patients.
The award ceremony will take place on February 4, 2025, coinciding with World Cancer Day.
The Gustave Roussy Prize is supported by Pierre Fabre Laboratories as founding sponsor.
Submit your application here: https://forms.office.com/e/rBSaqphxwG
Last news
-
ADCs: Two Landmark Publications in Cancer Cell and Nature Medicine Showcase Gustave Roussy's Expertise
In less than two months, researchers and clinicians from Gustave Roussy have contributed to two major publications on Antibody-Drug Conjugates (ADCs) in Cancer Cell and Nature Medicine. Together, these papers provide both a comprehensive overview of current knowledge and a strategic vision to accelerate the development of the next generation of these innovative therapies.
-
Drug shortages: Gustave Roussy becomes the only Cancer Centre in France authorised to produce Special Hospital Preparations
The Clinical Pharmacy Department at Gustave Roussy has been authorised by the French Ministry of Health to manufacture Special Hospital Preparations (SHPs). Granted for a period of seven years, this accreditation enables the Institute’s hospital pharmacy to produce certain medicines in coordination with the French National Agency for the Safety of Medicines and Health Products (ANSM) and the Ministry of Health. Gustave Roussy is the only French Comprehensive Cancer Centre (CLCC) authorised to manufacture Special Hospital Preparations, alongside ten university hospitals.
-
Personalising Breast Cancer Treatments: 5 Questions with Dr Barbara Pistilli
Advances in treatment and patient care mean that five-year net survival for breast cancer now reaches 88%1 in France. However, with around 60,000 new cases diagnosed each year in France alone, breast cancer remains a major public health challenge. One reason is the side effects associated with treatment. In response to this issue, Dr Barbara Pistilli, Head of the Breast Cancer Committee at Gustave Roussy, advocates an approach centred on personalised care, ensuring that each woman receives a treatment intensity tailored to her tumour and individual journey, without compromising her chances of recovery.
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
